NCT05272709View on ClinicalTrials.gov

TT-702 in Patients With Advanced Solid Tumours.

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

188

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Advanced Solid Tumors
Interventions
DRUG

TT-702

TT-702 will be administered orally, once daily, for up to 12 months.

DRUG

Darolutamide

Darolutamide will be administered orally, twice daily, for up to 12 months.

Trial Locations (3)

SM2 5PT

RECRUITING

Royal Marsden Hospital NHS Foundation Trust, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

SO16 6YD

RECRUITING

University Hospital Southampton NHS Foundation Trust, Southampton

Sponsors

Lead Sponsor

Cancer Research UK
All Listed Sponsors
collaborator

Teon Therapeutics, Inc.

INDUSTRY

lead

Cancer Research UK

OTHER